1. Home
  2. BCDA vs FBGL Comparison

BCDA vs FBGL Comparison

Compare BCDA & FBGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • FBGL
  • Stock Information
  • Founded
  • BCDA N/A
  • FBGL 1996
  • Country
  • BCDA United States
  • FBGL Singapore
  • Employees
  • BCDA N/A
  • FBGL N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • FBGL Miscellaneous manufacturing industries
  • Sector
  • BCDA Health Care
  • FBGL Consumer Discretionary
  • Exchange
  • BCDA Nasdaq
  • FBGL Nasdaq
  • Market Cap
  • BCDA 9.4M
  • FBGL 8.1M
  • IPO Year
  • BCDA N/A
  • FBGL 2025
  • Fundamental
  • Price
  • BCDA $2.32
  • FBGL $0.62
  • Analyst Decision
  • BCDA Strong Buy
  • FBGL
  • Analyst Count
  • BCDA 1
  • FBGL 0
  • Target Price
  • BCDA $25.00
  • FBGL N/A
  • AVG Volume (30 Days)
  • BCDA 102.2K
  • FBGL 360.1K
  • Earning Date
  • BCDA 05-14-2025
  • FBGL 01-01-0001
  • Dividend Yield
  • BCDA N/A
  • FBGL N/A
  • EPS Growth
  • BCDA N/A
  • FBGL N/A
  • EPS
  • BCDA N/A
  • FBGL 0.04
  • Revenue
  • BCDA $58,000.00
  • FBGL $15,607,369.00
  • Revenue This Year
  • BCDA N/A
  • FBGL N/A
  • Revenue Next Year
  • BCDA N/A
  • FBGL N/A
  • P/E Ratio
  • BCDA N/A
  • FBGL $18.50
  • Revenue Growth
  • BCDA N/A
  • FBGL 25.78
  • 52 Week Low
  • BCDA $1.63
  • FBGL $0.44
  • 52 Week High
  • BCDA $6.15
  • FBGL $5.45
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 45.74
  • FBGL N/A
  • Support Level
  • BCDA $2.40
  • FBGL N/A
  • Resistance Level
  • BCDA $2.92
  • FBGL N/A
  • Average True Range (ATR)
  • BCDA 0.31
  • FBGL 0.00
  • MACD
  • BCDA -0.00
  • FBGL 0.00
  • Stochastic Oscillator
  • BCDA 9.28
  • FBGL 0.00

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial and industrial building projects. As a green contractor focused on environmentally sound practices, It aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, lead lining, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts, sales of construction materials, and rendering of services.

Share on Social Networks: